BiomX Inc. (PHGE) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

BiomX Inc. (PHGE) Healthcare & Pipeline Overview

BiomX Inc. is a clinical-stage biotechnology company pioneering phage-based therapies to target and eradicate specific harmful bacteria associated with chronic diseases and skin conditions. Their innovative approach positions them within the rapidly evolving microbiome therapeutics market, targeting unmet needs in areas like cystic fibrosis and inflammatory bowel diseases.

What Is the Investment Thesis for PHGE?

BiomX Inc. presents a compelling, albeit high-risk, investment opportunity within the microbiome therapeutics space. The company's phage-based technology offers a novel approach to targeting and eliminating harmful bacteria, potentially addressing unmet needs in various chronic diseases. Key value drivers include the successful completion of ongoing clinical trials for BX004, BX005, and BX003, with Phase 2 data expected in 2027. Positive clinical data could lead to significant partnerships or acquisition interest from larger pharmaceutical companies. However, the company's limited cash runway and the inherent risks associated with clinical-stage biotechnology companies necessitate careful consideration. The company's market cap is currently $0.00B, reflecting the early stage of its development.

Based on FMP financials and quantitative analysis

PHGE Key Highlights

BiomX is a clinical-stage company with a focus on microbiome-based therapies.

• Lead product candidate BX004 is in Phase 1b/2a clinical trials for cystic fibrosis patients with Pseudomonas aeruginosa infections.
• Pipeline includes BX005, a topical phage cocktail in Phase 1/2 clinical study for atopic dermatitis targeting Staphylococcus aureus.
• BX003 is an orally administered phage cocktail in Phase 1b/2a development for IBD and PSC patients.
• Colorectal cancer program utilizes engineered phage to target Fusobacterium nucleatum in the tumor microenvironment.

Who Are PHGE's Competitors?

PHGE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are PHGE's Key Strengths?

Novel phage-based technology platform.

• Diverse pipeline of product candidates.
• Experienced management team.
• Strong intellectual property position.

What Are PHGE's Weaknesses?

Clinical-stage company with no approved products.

• Limited financial resources.
• High risk of clinical trial failure.
• Dependence on strategic partnerships.

What Could Drive PHGE Stock Higher?

Phase 2 clinical trial results for BX004 in cystic fibrosis patients (expected in 2027).

• Phase 1/2 clinical trial results for BX005 in atopic dermatitis patients (expected in 2027).
• Advancement of BX003 into later-stage clinical trials for IBD and PSC.
• Potential strategic partnerships with pharmaceutical companies.

What Are the Key Risks for PHGE?

Financial-distress signal — its Altman Z-Score of -15.34 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $5.7M recently.
• Clinical trial failures for BX004, BX005, and BX003.
• Regulatory hurdles in obtaining marketing approval for phage-based therapies.
• Competition from other companies developing microbiome therapeutics.
• Limited financial resources and the need to raise additional capital.

What Are the Growth Opportunities for PHGE?

• Expansion of BX004 into additional indications: Beyond cystic fibrosis, Pseudomonas aeruginosa infections are prevalent in other respiratory conditions, such as bronchiectasis and ventilator-associated pneumonia. Expanding the clinical development of BX004 to these indications could significantly increase its market potential. The market for Pseudomonas aeruginosa infection treatment is expected to reach $2.1 billion by 2030.
• Advancement of BX005 for atopic dermatitis: Atopic dermatitis is a chronic inflammatory skin condition affecting millions worldwide. Successful development and commercialization of BX005 as a topical phage cocktail targeting Staphylococcus aureus could capture a significant share of the atopic dermatitis treatment market, projected to reach $16.5 billion by 2027.
• Development of BX003 for IBD and PSC: Inflammatory bowel diseases (IBD) and primary sclerosing cholangitis (PSC) are chronic inflammatory conditions with limited treatment options. BX003, targeting a bacterial target in the gut, has the potential to address the underlying cause of these diseases. The IBD market is expected to reach $25.2 billion by 2028, while the PSC market is estimated at $1.1 billion by 2025.
• Strategic partnerships with pharmaceutical companies: Collaborating with larger pharmaceutical companies for clinical development, manufacturing, and commercialization could accelerate the progress of BiomX's pipeline and provide access to resources and expertise. Strategic partnerships can also provide non-dilutive funding and validation of BiomX's technology.
• Expansion of the colorectal cancer program: The colorectal cancer program, utilizing engineered phage to target Fusobacterium nucleatum, represents a novel approach to cancer therapy. Expanding this program to other cancers where Fusobacterium nucleatum plays a role could broaden its applicability. The global colorectal cancer therapeutics market is projected to reach $14.3 billion by 2027.

What Are PHGE's Competitive Advantages?

• Proprietary phage technology platform.
• Intellectual property protection for their phage therapies.
• Expertise in microbiome research and phage engineering.
• First-mover advantage in developing phage-based therapies for specific indications.

What Does PHGE Do?

Founded in 2015 and headquartered in Ness Ziona, Israel, BiomX Inc. is a clinical-stage microbiome company at the forefront of developing innovative therapies using natural and engineered phage technologies. These technologies are designed to precisely target and kill specific harmful bacteria that contribute to various diseases. The company's focus spans a range of conditions, including those affecting the skin's appearance and chronic diseases like inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). BiomX's lead product candidate, BX004, is a phage therapy specifically designed for CF patients suffering from chronic Pseudomonas aeruginosa respiratory infections. This therapy is currently undergoing Phase 1b/2a clinical trials. The company's pipeline also includes BX005, a topical phage cocktail in Phase 1/2 clinical study targeting Staphylococcus aureus (S. aureus), a bacterium linked to atopic dermatitis. Additionally, BX003, an orally administered phage cocktail, is in Phase 1b/2a development, targeting a bacterial target present in the gut of IBD and PSC patients. BiomX is also advancing a colorectal cancer program that utilizes engineered phage with various payloads, administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX's approach leverages the natural ability of phages to selectively target and eliminate bacteria, offering a potential alternative to traditional antibiotics and a more precise way to modulate the microbiome for therapeutic benefit.

What Products and Services Does PHGE Offer?

• Develop phage-based therapies to target and kill specific harmful bacteria.
• Focus on conditions affecting the skin's appearance and chronic diseases.
• Develop BX004 for cystic fibrosis patients with Pseudomonas aeruginosa infections.
• Develop BX005 for atopic dermatitis targeting Staphylococcus aureus.
• Develop BX003 for IBD and PSC patients targeting a bacterial target in the gut.
• Engage in a colorectal cancer program targeting Fusobacterium nucleatum.

How Does PHGE Make Money?

• Develop and commercialize phage-based therapies.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval for their products.
• Potentially partner with pharmaceutical companies for commercialization.

What Industry Does PHGE Operate In?

BiomX operates within the rapidly evolving microbiome therapeutics market. This market is driven by increasing understanding of the role of the microbiome in human health and disease. The competitive landscape includes companies developing therapies based on live bacteria, fecal transplants, and phage technologies. BiomX's phage-based approach offers a unique advantage in terms of precision and safety. The global microbiome therapeutics market is projected to reach $10.9 billion by 2027, growing at a CAGR of 21.3% from 2022, presenting significant opportunities for companies like BiomX.

Who Are PHGE's Key Customers?

• Patients with cystic fibrosis, IBD, PSC, atopic dermatitis, and colorectal cancer.
• Healthcare providers who treat these patients.
• Pharmaceutical companies interested in licensing or acquiring their technologies.

Over the past six months, BiomX Inc. insiders filed 8 SEC Form 4 transactions — 6 sales and 2 purchases. On net that is roughly 4.6M shares disposed (about $5.7M), a signal worth weighing alongside the fundamentals.

BiomX Inc. has beaten Wall Street's EPS estimate in 4 of its last 7 reported quarters — more hits than misses. Reported results have landed about 128.3% below estimates on average.

BiomX Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.34 places it in the distress zone, a signal of elevated financial risk.

BiomX Inc. (PHGE) Valuation Context

Relative to its peer group, PHGE's quantitative score of 16/100 is below the peer average of 88/100.

PHGE Revenue & Earnings Trend

In Q2 FY2026, PHGE generated $332K in top-line revenue. The company recorded a net loss of $3.8M, with diluted EPS of $-3.66. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, PHGE averaged $-0.97 in diluted EPS.

Company Profile

BiomX Inc. operates in the Aerospace & Defense industry within the Industrials sector. It is headquartered in Dover, US. The company is led by CEO Michael Oster. PHGE has traded publicly since 2019.

PHGE Financials

PHGE Latest News

PHGE Analyst Consensus

PHGE MoonshotScore

Latest BiomX Inc. Analysis

Common Questions About PHGE (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources